-
-
-
-
-
-
-
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Tops Q2 EPS by 10c
-
-
-
-
-
-
-
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arvinas (ARVN) and Pfizer (PFE) Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
-
-
-
-
-
-
-
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Tops Q2 EPS by 40c
-
1,199,634 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

